Fléchaire A, Colle B, Bernard P, Dupuy O, Philippe P
Service de médecine interne, HIA Desgenettes, Lyon, France.
Rev Med Interne. 1996;17(2):157-62. doi: 10.1016/0248-8663(96)82967-5.
Hemophagocytic syndromes are the clinicobiological translation of an unconnected macrophagic activity with hemophagocytosis. Their physiopathology is related with a deregulation of the T lymphocytes and an excessive production of cytokines. Acquired hemophagocytic syndromes are mostly associated with underlying pathology which they can reveal: immunodeficiency, infections (mostly of viral origin), hemopathies and cancers, auto-immune diseases. The main clinicobiological features are fever, hepatosplenomegaly and peripheric bicytopeny. In the majority of cases, the diagnosis is confirmed by a myelogram which shows the presence of benign histiocytes, actively phagocyting the hematopoietic cells. The pejorative prognosis of hemophagocytic syndromes (actual mortality rate 30 to 45%) requires an early therapy which associates etiological treatment of the underlying affection with pathogenic treatment (pulse of corticosteroids, immunoglobulins, immunosuppressors, or plasmapheresis).
噬血细胞综合征是一种伴有噬血细胞现象的非连续性巨噬细胞活性的临床生物学表现。其病理生理学与T淋巴细胞失调和细胞因子过度产生有关。获得性噬血细胞综合征大多与潜在疾病相关,这些疾病可通过噬血细胞综合征得以揭示:免疫缺陷、感染(主要为病毒感染)、血液病和癌症、自身免疫性疾病。主要的临床生物学特征为发热、肝脾肿大和外周血两系血细胞减少。在大多数病例中,骨髓检查显示存在良性组织细胞,这些细胞积极吞噬造血细胞,从而确诊该病。噬血细胞综合征预后不良(实际死亡率为30%至45%),需要早期治疗,即针对潜在疾病进行病因治疗并联合病原学治疗(使用大剂量糖皮质激素、免疫球蛋白、免疫抑制剂或进行血浆置换)。